Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduction of the HIV-1 reservoir in T cells from people with HIV-1 on suppressive antiretroviral therapy using expanded natural killer cells.

mBio·2026
Same author

<i>In vivo</i> tracking of CAR-T cells in tumors <i>via</i> nanobubble-based contrast enhanced ultrasound.

Nanoscale horizons·2026
Same author

Modeling and inferring metacommunity dynamics with Maximum Caliber.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Human Coronavirus HKU1 Neutralizing Monoclonal Antibodies Target Diverse Epitopes Within and Around the TMPRSS2 Receptor Binding Site.

bioRxiv : the preprint server for biology·2025
Same author

A novel feeder cell based on 4-1BBL and membrane-bound IL-21/IL-15 induce highly expansion and anti-tumor effect of natural killer cells.

BMC biotechnology·2025
Same author

In vivo tracking of CAR-T cells in tumors via nanobubble-based contrast enhanced ultrasound.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Jun 29, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.0K

Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin's Lymphoma.

Maria Florencia Giraudo1, Zachary Jackson1, Indrani Das1

  • 1Department of Pathology, Case Western Reserve University, Cleveland, Ohio.

Pathogens & Immunity
|March 29, 2024
PubMed
Summary

Chimeric antigen receptor (CAR)-T cell therapy offers a promising personalized treatment for non-Hodgkin

Keywords:
CAR-TCell TherapyChimeric Antigen ReceptorsImmunotherapyLymphoma

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

504
Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

844

Related Experiment Videos

Last Updated: Jun 29, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.0K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

504
Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

844

Area of Science:

  • Oncology
  • Immunotherapy
  • Cellular Therapy

Background:

  • Non-Hodgkin's lymphoma (NHL) presents a poor prognosis despite conventional treatments.
  • Chimeric antigen receptor (CAR)-T cell therapy is an emerging personalized treatment option for NHL.
  • CAR-T cells are engineered T cells designed to target and lyse tumor cells expressing specific antigens.

Purpose of the Study:

  • To review the application of CAR-T cell therapy in treating non-Hodgkin's lymphoma.
  • To discuss the mechanisms, clinical trial outcomes, and challenges associated with CAR-T cell therapy for NHL.

Main Methods:

  • Review of clinical trials and scientific literature on CAR-T cell therapy for NHL.
  • Analysis of CAR construct design targeting B-cell antigens (CD19, CD20, CD22).
  • Evaluation of treatment outcomes and resistance mechanisms in NHL patients.

Main Results:

  • CAR-T cell therapies have shown promising results in clinical trials (e.g., ZUMA-7, TRANSFORM) for relapsed/refractory NHL.
  • FDA approval has been granted for CAR-T cell treatments in specific NHL cases.
  • CAR-T therapy has demonstrated improved clinical outcomes for NHL patients.

Conclusions:

  • CAR-T cell therapy represents a significant advancement in personalized medicine for NHL.
  • Despite challenges like adverse effects and tumor resistance, CAR-T therapy offers optimism for future NHL treatment.
  • Ongoing research aims to overcome limitations and enhance the efficacy of CAR-T cell therapy in NHL.